Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 15.8% from a year ago
Total current assets stood at $544.92M at the end of Q1 FY2026, up 15.8% from a year earlier and up 29.1% from the prior quarter. Over 3 fiscal years it compounded at +339.1% a year.
Context
- Total current assets amounted to 98.4% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +15.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 422.05M USD
- Year-over-year change
- -16.0%
- 3-year CAGR
- +339.1%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 422.05M | -16.0% |
| FY2024 | 2024-12-31 | 502.53M | +117.5% |
| FY2023 | 2023-12-31 | 231.07M | +4536.3% |
| FY2022 | 2022-12-31 | 4.98M | — |
Total Current Assets vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 total current assets of $544.92M is the highest of the 6 companies compared; the peer median is $195.56M.
- Its year-over-year change of +15.8% is the 3rd highest of 6, against a peer median of +13.7%.
- Total current assets amounts to 98.4% of total assets for BCAX, versus a peer median of 95.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $544.92M | +15.8% | +339.1% | 98.4% |
| Mar 2026 | $361.41M | +13.7% | -6.6% | 89.7% | |
| Mar 2026 | $195.69M | +57.6% | +2.5% | 95.4% | |
| Mar 2026 | $195.56M | +3163.6% | +67.1% | 98.2% | |
| Mar 2026 | $182.52M | +0.2% | -0.3% | 83.8% | |
| Mar 2026 | $58.52M | -36.9% | +21.8% | 99.4% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $195.56M | +13.7% | +2.5% | 95.4% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.